Emodin succinate monoethyl ester (ESME, Kanglexin) is a small molecule AdipoR2 agonist, activates AdipoR2, inhibits hepatic lipogenesis, promotes fatty acid oxidation, and alleviates experimental hepatic steatosis in vivo, also inhibits NLRP3 inflammatory body activation and cell pyroptosis.
Emodin succinate monoethyl ester (ESME, Kanglexin) activates AdipoR2, AMPK and PPARα, and reduces lipid deposition in palmitic acid or oleic acid-induced HepG2 and L02 cells.
Suppression of AdipoR2 expression or AMPK activation completely eliminates the effect of ESME on reducing lipid accumulation in hepatocytes.
Emodin succinate monoethyl ester (ESME, Kanglexin) reduces liver lipid production and accumulation, and alleviates hepatic steatosis in hamsters and Apoe−/− mice induced by high-fat diet.
Emodin succinate monoethyl ester (ESME, Kanglexin) showed prepotent efficacy and safety in reducing hepatic steatosis and protecting hepatocytes.